Patent · US Active

Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal

US7858116B2 · kind B2 · utility

7Cited by
2References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 20, 2006
Grant dateDec 28, 2010
Priority date
Expiry dateAug 1, 2029

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P3/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.